Heidelberg

• ABTECT-1 – ABX464 Treatment Evaluation for ulcerative Colitis Therapy -1 Not authorised
  2022-500535-36-00 5 Moderately to severely active ulcerative colitis
• ABTECT-Maintenance – ABX464 Treatment Evaluation for ulcerative Colitis Therapy Not authorised
  2022-500537-84-00 5 Moderately to severely active ulcerative colitis
• Clinical trial of MK-7648A in adults and children with skin cancer Not authorised
  2022-501417-31-00 5 High-risk Resected Melanoma
• Combining Loncastuximab Tesirine and Epcoritamab in Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL) Not authorised
  2023-509861-19-00 4 Diffuse large B-cell lymphoma (DLBCL)
• Study to Evaluate the Efficacy and Safety of ATI-045 in Atopic Dermatitis Not authorised
  2024-520302-19-00 4 Atopic dermatitis
• A 3-month, phase 2, single-blind, randomised, no-treatment controlled study assessing efficacy and safety of Renaparin® for improvement of k … Pending
  2022-501389-23-02 4 end-stage renal disease or otherwise an insufficient kidney function
• Randomised efficacy and safety clinical trial of PQ Birch in subjects with seasonal allergic rhinitis and/or rhinoconjunctivitis induced by … Pending
  2023-507427-28-00 5 seasonal allergic rhinitis and/or rhinoconjunctivitis
• A study to investigate efficacy of RP2 with nivolumab compared to ipilimumab with nivolumab in adult patients with advanced uveal melanoma n … Pending
  2023-508784-68-00 10 metastatic uveal melanoma
• PNOC029_Tovorafenib for the treatment of newly diagnosed or recurrent craniopharyngioma in children and young adults Pending
  2024-511510-20-00 4 craniopharyngioma
• A prospective, open-label, randomized, multicenter phase-III trial to evaluate the efficacy of pirtobrutinib and epcoritamab compared with R … Pending
  2024-513445-37-00 5 previously untreated RT, irrespective of risk factors and disease stag
• Extension Study of ACT-EARLY Pending
  2024-513676-18-00 5 Transthyretin Amyloidosis
• SIOP PNET 5 medulloblastoma Pending
  2024-513724-42-00 10 Medulloblastoma
• A study to evaluate the efficacy of oxaliplatin- or gemcitabine-based chemotherapy after allocation by standard criteria or by genetic marke … Pending
  2024-514682-19-00 5 Resected pancreatic ductal adenocarcinoma
• Phase I/II combination umbrella trial in progressive/relapsed/refractory pediatric low-grade glioma (pLGG) (EPILOGUE) Pending
  2024-516896-34-00 9 progressive/relapsed/refractory pediatric low-grade glioma (pLGG)
• Comparison of neurocognitive outcome in two standard regimen for treatment of low-risk medulloblastoma (COGNITO-MB) Pending
  2024-517133-40-00 5 newly diagnosed, non-metastatic, SHH-activated, TP53-wt, non-MYC ampli
• Atezolizumab, Pertuzumab and Trastuzumab with chemotherapy as neoadjuvant treatment of HER2 positive early high-risk and locally advanced br … Pending
  2024-518026-32-00 5 Invasive Breast Cancer
• An Adaptive Program of IKT-001 in Pulmonary Arterial Hypertension (PAH). Pending
  2024-520218-23-00 10 Pulmonary Arterial Hypertension
• OCEAN(a)-PreEvent - Olpasiran trials of Cardiovascular Events And LipoproteiN(a) reduction to Prevent first major cardiovascular Events Pending
  2025-520554-11-00 5 Cardiovascular Disease
• DAREON®-Lung-1: A study in people with advanced small cell lung cancer to compare obrixtamig plus atezolizumab, carboplatin, and etoposide t … Pending
  2025-520565-51-00 5 small cell lung cancer
• A study to test different doses of BI 3923948 alone and in combination with an anti-PD-1 antibody in people with different types of advanced … Pending
  2025-521438-27-00 1 advanced, unresectable and/or metastatic solid tumors
• A Randomized, Active-Controlled, Double-blind, Multicenter, Phase 3 Clinical Study of Ivonescimab in Combination with FOLFOX versus Bevacizu … Pending
  2025-521587-35-00 5 Metastatic colorectal cancer
• (22597) A study to learn about how safe nitroglycerin is and how it affects the body when taken along with nurandociguat in people with coro … Pending
  2025-522335-34-00 3 Chronic kidney disease
• A Study of Vepugratinib (LY3866288) in Participants with Cancer in the Urinary Tract ( FORAGER-2 ) Pending
  2025-522855-25-00 5 Carcinoma, Transitional Cell
• Phase Ib Dose-Ranging Study of the Safety, PK, PD & Efficacy of the Activin Signaling Inhibitor HS235 vs placebo added to background therapy … Pending
  2025-523010-89-00 3 Pulmonary arterial hypertension

Showing 1–24 of 732 trials